PDS Biotechnology Corp
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
PDSB$1.03-4.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(7,349,056) | $(8,488,967) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 1,156,495 | 1,253,882 |
| Issuance of shares in consulting agreements | - | 203,501 |
| Amortization of debt discount | 448,837 | 272,578 |
| Depreciation expense | 5,459 | 5,459 |
| Finance lease depreciation expense | 9,670 | 9,670 |
| Changes in assets and liabilities: | ||
| Prepaid expenses and other assets | 764,455 | (3,395,931) |
| Accounts payable | 75,904 | 1,174,424 |
| Accrued expenses | 516,590 | (66,872) |
| Net cash used in operating activities | (4,371,646) | (9,032,256) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of pre-funded warrants | - | 1,009,969 |
| Proceeds from exercise of pre-funded warrants | - | 71 |
| Proceeds from issuance of warrants | - | 2,150,771 |
| Payments of finance lease obligations | (13,198) | (14,761) |
| Loan principal repayment | (1,500,000) | (3,125,000) |
| Proceeds from issuance of common stock from at-the-market program, net of issuance costs | 833,371 | 306,115 |
| Proceeds from issuance of common stock, net of issuance costs | - | 6,994,174 |
| Net cash provided by financing activities | (679,827) | 7,321,339 |
| Net increase in cash and cash equivalents | (5,051,473) | (1,710,917) |
| Cash and cash equivalents at beginning of period | 26,711,969 | 41,689,591 |
| Cash and cash equivalents at the end of period | $21,660,496 | $39,978,674 |
| Supplemental information of cash and non-cash transactions: | ||
| Cash paid for interest | $564,653 | $693,989 |
Index
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.